On July 29th, Pfizer announced the merger of its off-patent drug business with generic drugmaker ... [+] Mylan. Coincidentally, the only other Pfizer insider to have bought shares in the past nine years also serves on Pfizer’s Science and Technology Committee. On July 30, 2020, it was announced that Cerevel Therapeutics was merging with a “public special purpose acquisition company” (SPAC) called Arya Sciences Acquisition Corp II. Once the deal is complete, Cerevel Therapeutics Holdings will trade on the Nasdaq under the ticker symbol “CERE” by Q4 2020. The Edge believes there’s at least three good reasons for investors to be confident in Pfizer going forward to 2021, just as insiders Mr Blaylock and Dr Gottlieb are.

Source: Forbes August 25, 2020 09:45 UTC